Results 211 to 220 of about 66,449 (275)

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 5, May 2026.
ABSTRACT Aim Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.
Yoh Watanabe, Tsukasa Baba, Shu Soeda, Hideki Tokunaga, Wataru Yamagami, Hiroyuki Nomura, Yoichi Kobayashi, Kei Kawana, Kiyoshi Yoshino, Yoshihito Yokoyama, Hirotaka Nishi, Hiroaki Kobayashi, Yukiko Matsuzawa, Shunsuke Oyamada, Satoru Takahashi, Satoru Nagase   +15 more
wiley   +1 more source

Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy. [PDF]

Mater Today Bio
Tian M, Meng X, Song W, Wu Z, Liu Y, Dong X, Ren S, Du J, Zhao P.   +8 more
europepmc   +1 more source

APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells. [PDF]

Cell Death Dis
Tao L, Zhao Y, Jiang Z, Kong S, Ding Y, Ni T, Wang W, Liu Y.   +7 more
europepmc   +1 more source

Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Interventions for cancer‐related cognitive impairment are understudied, particularly during therapy. Methods Patients with cancer receiving chemotherapy reporting cognitive problems were randomized to one of four study arms for 6 weeks in this phase 2 randomized controlled trial with a 2 × 2 factorial design.
Michelle C. Janelsins, Riham A. Alieldin, Tyler Holler, Hongying Sun, Po‐Ju Lin, Michelle Shayne, Alissa Huston, Kassandra Doyle, Michelle Porto, Mohamedtaki Tejani, Bryan Thompson, Allison Magnuson, Marcia Krebs, Richard F. Dunne, Supriya G. Mohile, Chin‐Shang Li, Umang Gada, Ajay Dhakal, Aram F. Hezel, Marcus S. Noel, Alok A. Khorana, Brian D. Yirinec, Nayana Kamath, David W. Dougherty, Tim A. Ahles, Gary R. Morrow, Karen M. Mustian   +26 more
wiley   +1 more source

Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. [PDF]

Oncol Rep
Zheng R, Liu Y, Zhou S, Liu G, Liu X, Yang Y, Zhang Y.   +6 more
europepmc   +1 more source

Mechanisms of gemcitabine resistance in pancreatic cancer [PDF]

, 2018
openaire   +1 more source

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer. [PDF]

J Biomed Sci
Jeong EJ, Roh Y, Jung E, Hwang JS, Son T, Ban HS, Han TS, Choo YK, Kim JS.   +8 more
europepmc   +1 more source

RETRACTION: Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma. [PDF]

Dis Markers
Markers D.
europepmc   +1 more source

CircRNA_103809/miR-516a/FBXL18 contributes to stemness and gemcitabine resistance of bladder cancer cells. [PDF]

Arch Med Sci
Yang Y, Wang F, Ning W, Ding Y, Chen W, Yu Z.   +5 more
europepmc   +1 more source

MS CETSA deep functional proteomics uncovers DNA repair programs leading to gemcitabine resistance. [PDF]

Nat Commun
Liang YY, Khalid K, Le HV, Teo HMV, Raitelaitis M, Gerault MA, Lee JJH, Lyu J, Chan A, Jeyasekharan AD, Tam WL, Nordlund P, Prabhu N.   +12 more
europepmc   +1 more source